Skip to Main Content
Table 2

Comparison of this fixed dose study (CALGB 9763) to the arm of the randomized Phase III study (CALGB 9342) that used paclitaxel 210 mg per square meter of BSA: Data are for cycle 1 of single-agent therapy

Number of patients evaluable (enrolled)Mean (SD)MinimumMedianMaximum
CALGB 9763 Paclitaxel 360 mg      
 Paclitaxel (mg/m226 (32) 214 (34) 164 203 300 
 BSA (m226 (32) 1.72 (0.26) 1.20 1.77 2.19 
 Nadir WBC (per μL) 26 (32) 3,500 (1,880) 1,400 3,050 9,600 
 Nadir ANC (per μL) 26 (32) 1,620 (1,540) 20 1,020 6,300 
CALGB 9342 Paclitaxel 210 mg/m2      
 Paclitaxel (mg) 155 (156) 369 (37) 289 370 546 
 BSA (m2155 (156) 1.76 (0.18) 1.09 1.76 2.60 
 Nadir WBC (per μL) 143 (156) 2,780 (1,640) 400 2,400 7,600 
 Nadir ANC (per μL) 141 (156) 1,170 (1,190) 20 730 5,930 
Number of patients evaluable (enrolled)Mean (SD)MinimumMedianMaximum
CALGB 9763 Paclitaxel 360 mg      
 Paclitaxel (mg/m226 (32) 214 (34) 164 203 300 
 BSA (m226 (32) 1.72 (0.26) 1.20 1.77 2.19 
 Nadir WBC (per μL) 26 (32) 3,500 (1,880) 1,400 3,050 9,600 
 Nadir ANC (per μL) 26 (32) 1,620 (1,540) 20 1,020 6,300 
CALGB 9342 Paclitaxel 210 mg/m2      
 Paclitaxel (mg) 155 (156) 369 (37) 289 370 546 
 BSA (m2155 (156) 1.76 (0.18) 1.09 1.76 2.60 
 Nadir WBC (per μL) 143 (156) 2,780 (1,640) 400 2,400 7,600 
 Nadir ANC (per μL) 141 (156) 1,170 (1,190) 20 730 5,930 

Abbreviations: BSA, body surface area; ANC, absolute neutrophil count.

Close Modal

or Create an Account

Close Modal
Close Modal